Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Marizyme, Inc. (MRZM)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
555 Heritage Drive 33458
Jupiter, FL, US
Jupiter, FL, US
CEO
David L. Barthel
Website
marizyme.com
IPO
2010-11-10
CIK 1413754 ISIN US5703721028
Description
Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.7K
Beta
0.97
Float Shares
85.64M
Free Float %
65.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -99.77% | -99.98% | -99.80% | -99.97% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-14.73
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+176.6% ★ Q3'24: -100.0% (vs Q3'23)
-
EPS growth Biotechnology: +29.7%-62.8% Q3'24: +97.4% (vs Q3'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-13,477.5%
-
EBIT margin Biotechnology: +0.0%-8,715.4%
-
ROIC Biotechnology: -16.1%-404.7% Q3'24: -30.9% (vs Q3'23)
-
Share dilution Biotechnology: -3.4%+11.7% Q3'24: +187.7% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.37× Q3'24: -10.35× (vs Q3'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|
| Revenue |
233.5K
est: 233.5K (+0.0%)
|
645.8K
est: 467.0K (+38.3%)
|
700.5K
est.
|
| EBITDA |
-34.54M
est: -140.1K (-24,552.0%)
|
-55.44M
est: -280.2K (-19,688.5%)
|
-420.3K
est.
|
| EBIT |
-35.38M
est: -140.1K (-25,152.6%)
|
-56.29M
est: -280.2K (-19,988.7%)
|
-420.3K
est.
|
| Net Income |
-38.17M
|
-69.54M
|
—
est.
|
| SGA |
8.33M
|
17.06M
|
— |
| EPS |
-0.94
|
-1.53
|
— |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.32M
OE per share TTM
-0.06
Owner's Yield
-13,452.76%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
363.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
8
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SANDY J. MASSELLI | 10.40M | 85.00% | 10.40M | — | 10.40M | 10.00 | IN | UNITED STATES | 2009-09-21 | ↗ |
| 2 | BWL Investments Ltd | 9.79M | 17.89% | 9.79M | — | 9.79M | — | CO | Canada | 2023-07-12 | ↗ |
| 3 | Braeden Lichti | 9.79M | 17.89% | 9.79M | — | 9.79M | — | IN | Canada | 2023-07-12 | ↗ |
| 4 | ESC Holdings LLC | 2.56M | 13.10% | 2.56M | — | 2.56M | — | OO | New Jersey | 2023-03-31 | ↗ |
| 5 | Emmanuelle Schleipfer-Conley | 2.56M | 13.10% | — | 2.56M | — | 2.56M | IN | New Jersey | 2023-03-31 | ↗ |
| 6 | s | 2.31M | 6.42% | — | 2.31M | — | 10.00 | IN | Chile | 2021-06-08 | ↗ |
| 7 | Edward M. Giles | 1.60M | 6.90% | 1.60M | — | 1.60M | — | IN | United States of America | 2011-03-21 | ↗ |
| 8 | Stephen D. Baksa | 1.4K | 6.10% | 1.40M | — | 1.40M | — | IN | United States | 2011-03-21 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
250.0K
Cash buys
—
Cash sales
—
Net activity
-250,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-05 | Kampf Julie B. | Director | — | D | Options | 125,000 | 1.25 | 156.3K | 0 | — | ↗ |
| 2024-03-04 | Dhaduk Vithalbhai D | Director | — | D | Options | 125,000 | 1.25 | 156.3K | 0 | — | ↗ |
| 2023-12-21 | Braeden Lichti | 10% Owner | C-Conversion | D | Common stock | 3,815,294 | 0.10 | 381.5K | 13,293,841 | — | ↗ |
| 2023-11-30 | Very Donald Leroy JR | Officer | — | D | Options | 40,000 | 1.25 | 50.0K | 0 | — | ↗ |
| 2023-11-30 | Brooks Steven Scott | Officer | — | D | Options | 40,000 | 1.25 | 50.0K | 0 | — | ↗ |
| 2023-10-31 | CAMPBELL NEIL J | Director / Officer | — | D | Options | 500,000 | 1.25 | 625.0K | 0 | — | ↗ |
| 2023-08-29 | Lichti Braeden | 10% Owner | S-Sale | D | Common shares | 105,000 | 0.17 | 17.3K | 9,478,547 | — | ↗ |
| 2023-07-07 | Lichti Braeden | 10% Owner | P-Purchase | D | Common shares | 97,000 | 0.10 | 9.7K | 9,583,547 | — | ↗ |
| 2023-06-29 | Lichti Braeden | 10% Owner | S-Sale | D | Common shares | 106,327 | 0.09 | 9.6K | 9,680,547 | — | ↗ |
| 2023-04-14 | Dhaduk Vithalbhai D | Director / Officer / 10% Owner | D-Return | D | Warrant (right to buy) | 1,063,938 | 5.00 | 5.32M | 0 | — | ↗ |
| 2022-06-07 | STEWART MICHAEL R | Director | A-Award | A | Stock Option (right to buy) | 120,000 | 2.20 | 264.0K | 120,000 | — | ↗ |
| 2022-06-07 | Patel Nilesh Umedbhai | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-07 | Kampf Julie B. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-07 | Hearl William | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-07 | Dhaduk Vithalbhai D | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-07 | Brostowin Terry A | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-01 | STEWART MICHAEL R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-22 | Patel Nilesh Umedbhai | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-17 | Ross Harrison | Officer | A-Award | A | Stock Options (right to buy) | 273,750 | 0.09 | 24.6K | 273,750 | — | ↗ |
| 2022-03-17 | Kovalyov Georgiy | Officer | A-Award | A | Stock Options (right to buy) | 273,750 | 0.09 | 24.6K | 273,750 | — | ↗ |
| 2022-02-08 | Barthel David | Director / Officer | A-Award | A | Stock Options (right to buy) | 400,000 | 1.75 | 700.0K | 400,000 | — | ↗ |
| 2021-12-21 | Ross Harrison | Officer | — | I | Warrants (Right to Buy) | 100,000 | 1.26 | 126.0K | 0 | — | ↗ |
| 2021-12-21 | Kovalyov Georgiy | Officer | — | I | Warrants (Right to Buy) | 100,000 | 1.26 | 126.0K | 0 | — | ↗ |
| 2021-10-31 | Barthel David | Director / Officer | — | D | Employee Stock Option (Right to Buy) | 400,000 | 2.25 | 900.0K | 0 | — | ↗ |
| 2021-07-19 | Richmond Bradley | Officer | — | D | Common Stock | 0 | 0.00 | — | 52,088 | — | ↗ |
| 2021-04-02 | Richmond Bradley | Officer | — | D | Warrants (Right to Buy) | 36,364 | 1.38 | 50.0K | 0 | — | ↗ |
| 2021-03-05 | SAPIRSTEIN JAMES | Director / Officer | A-Award | A | Options | 125,000 | 1.25 | 156.3K | 1,350,000 | — | ↗ |
| 2021-03-05 | Hearl William | Director | A-Award | A | Stock Options (right to buy) | 125,000 | 1.25 | 156.3K | 125,000 | — | ↗ |
| 2021-03-05 | Brostowin Terry A | Director | A-Award | A | Options | 125,000 | 1.25 | 156.3K | 515,000 | — | ↗ |
| 2021-02-22 | Dhaduk Vithalbhai D | Director | — | I | Common Stock | 0 | 0.00 | — | 8,840,680 | — | ↗ |
| 2020-11-01 | CAMPBELL NEIL J | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 20,000 | — | ↗ |
| 2020-10-30 | Hearl William | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-22 | Harmon Bruce | Officer | A-Award | A | Option | 120,000 | 1.25 | 150.0K | 120,000 | — | ↗ |
| 2020-09-01 | Harmon Bruce | Officer | — | D | Common Stock | 0 | 0.00 | — | 40,000 | — | ↗ |
| 2020-07-31 | Pachuk Catherine J. | Officer | — | D | Common Stock | 0 | 0.00 | — | 268,710 | — | ↗ |
| 2020-07-31 | Dhaduk Vithalbhai D | Director | — | I | Warrants | 2,648,844 | 5.00 | 13.24M | 0 | — | ↗ |
| 2020-07-31 | Chandrasekhar Satishchandran | Officer | — | D | Warrants | 226,197 | 5.00 | 1.13M | 0 | — | ↗ |
| 2020-07-28 | Brooks Steven Scott | Officer | — | D | Common Stock | 0 | 0.00 | — | 20,000 | — | ↗ |
| 2019-07-13 | SAPIRSTEIN JAMES | Director / Officer | — | D | Non-Statutory Option to Purchase Common Stock | 1,095,000 | 1.01 | 1.11M | 0 | — | ↗ |
| 2019-07-13 | DeVito Nicholas | Officer | — | D | Common Stock | 0 | 0.00 | — | 900,000 | — | ↗ |
| 2019-07-13 | Brostowin Terry A | Director | — | D | Non-Statutory Option to Purchase Common Stock | 250,000 | 1.01 | 252.5K | 0 | — | ↗ |
| 2018-12-06 | SAPIRSTEIN JAMES | Director / Officer | — | D | Non-Statutory Option to Purchase Common Stock | 125,000 | 1.50 | 187.5K | 0 | — | ↗ |
| 2018-12-06 | Brostowin Terry A | Director | — | D | Non-Statutory Option to Purchase Common Stock | 140,000 | 1.50 | 210.0K | 0 | — | ↗ |
| 2018-11-11 | Schleipfer-Conley Emmanuelle | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,555,640 | — | ↗ |
| 2018-11-11 | Gutierrez Juan Francisco | Director | — | I | Common Stock | 0 | 0.00 | — | 264,000 | — | ↗ |
| 2013-10-16 | MOORE JOHN A JR | Director | P-Purchase | A | Common Stock | 100,000 | 0.35 | 35.0K | 550,960 | — | ↗ |
| 2013-04-29 | Ott Joerg | Director | A-Award | A | Common Stock Warrants (right to buy) | 100,000 | 0.25 | 25.0K | 100,000 | — | ↗ |
| 2013-04-29 | BAKSA STEPHEN D | Director | A-Award | A | Common Stock Warrants (right to buy) | 100,000 | 0.25 | 25.0K | 100,000 | — | ↗ |
| 2013-02-28 | MOORE JOHN A JR | Director | P-Purchase | A | Common Stock | 450,960 | 0.30 | 135.3K | 450,960 | — | ↗ |
| 2013-02-26 | BAKSA STEPHEN D | Director | X-InTheMoney | A | Common Stock Warrants (right to buy) | 500,000 | 0.20 | 100.0K | 0 | — | ↗ |
| 2012-10-26 | BAKSA STEPHEN D | Director | P-Purchase | A | Common Stock Warrants(right to buy) | 500,000 | 0.20 | 100.0K | 500,000 | — | ↗ |
| 2012-08-13 | MOORE JOHN A JR | Director | P-Purchase | A | Warrants (Right to buy) | 100,000 | 0.35 | 35.0K | 100,000 | — | ↗ |
| 2012-05-10 | ERNST MARKUS RAINER | Officer | P-Purchase | A | Common Stock | 30,000 | 1.50 | 45.0K | 30,000 | — | ↗ |
| 2012-04-16 | Ott Joerg | Director / Officer | P-Purchase | A | Common Stock | 120,000 | 1.50 | 180.0K | 420,000 | — | ↗ |
| 2012-03-26 | BAKSA STEPHEN D | Director | X-InTheMoney | A | Common Stock | 250,000 | 0.50 | 125.0K | 1,685,000 | — | ↗ |
| 2012-03-08 | BAKSA STEPHEN D | Director | P-Purchase | A | Common Stock | 5,000 | 1.65 | 8.3K | 1,435,000 | — | ↗ |
| 2012-03-01 | SHIHADAH MOHAMMAD AHMAD | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-03-01 | MOORE JOHN A JR | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-03-01 | DARSCH DAVID MICHAEL | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-03-01 | BAKSA STEPHEN D | Director | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 150,000 | — | ↗ |
| 2012-02-24 | ERNST MARKUS RAINER | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-02-01 | Durst Mark William | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-02-01 | Durst John Paul | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-10-11 | Durst Mark William | — | P-Purchase | A | Common Stock | 9,350 | 1.69 | 15.8K | 340,000 | — | ↗ |
| 2011-10-11 | Durst John Paul | — | P-Purchase | A | Common Stock | 9,350 | 1.69 | 15.8K | 340,000 | — | ↗ |
| 2011-10-07 | Durst Mark William | — | P-Purchase | A | Common Stock | 3,350 | 1.90 | 6.4K | 330,650 | — | ↗ |
| 2011-10-07 | Durst John Paul | — | P-Purchase | A | Common Stock | 4,650 | 1.90 | 8.8K | 330,650 | — | ↗ |
| 2011-09-26 | Durst Mark William | — | S-Sale | D | Common Stock | 700 | 2.33 | 1.6K | 327,300 | — | ↗ |
| 2011-09-16 | Durst John Paul | — | S-Sale | D | Common Stock | 2,000 | 2.15 | 4.3K | 326,000 | — | ↗ |
| 2011-09-14 | Durst Mark William | — | S-Sale | D | Common Stock | 9,000 | 2.06 | 18.5K | 328,000 | — | ↗ |
| 2011-09-14 | Durst John Paul | — | S-Sale | D | Common Stock | 12,000 | 2.06 | 24.7K | 328,000 | — | ↗ |
| 2011-09-12 | Durst Mark William | — | S-Sale | D | Common Stock, Par Value $0.001 | 3,000 | 2.50 | 7.5K | 337,000 | — | ↗ |
| 2011-06-16 | Durst Mark William | — | — | I | Common Stock, Par Value $0.001 | 0 | 0.00 | — | 340,000 | — | ↗ |
| 2011-06-16 | Durst John Paul | — | — | I | Common Stock, Par Value $0.001 | 0 | 0.00 | — | 340,000 | — | ↗ |
| 2010-11-08 | Ott Joerg | Director / Officer | P-Purchase | A | Common Stock | 300,000 | 1.17 | 351.0K | 300,000 | — | ↗ |
| 2010-04-26 | Ott Joerg | Director / Officer / 10% Owner | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 1,550,000 | — | ↗ |
| 2010-04-26 | LOTUS HOLDINGS LTD | 10% Owner | — | D | COMMON STOCK, PAR VALUE $0.001 | 0 | 0.00 | — | 5,077,250 | — | ↗ |
| 2009-09-21 | Masselli Sandy J Jr | Director / Officer / 10% Owner | — | D | COMMON STOCK, PAR VALUE $0.001 PER SHARE | 0 | 0.00 | — | 10,399,570 | — | ↗ |
| 2009-09-21 | LAM PUI SHAN | — | S-Sale | D | common stock | 5,538,000 | 0.12 | 664.6K | 462,000 | — | ↗ |
| 2009-09-21 | Fung Vanleo Y.W. | — | S-Sale | D | common stock | 250,000 | 0.33 | 82.5K | 100,000 | — | ↗ |
| 2008-04-17 | Fung Vanleo Y.W. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 350,000 | — | ↗ |
| 2008-04-01 | LAM PUI SHAN | Director / Officer / 10% Owner | — | D | Common stock | 0 | 0.00 | — | 6,000,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-43.3K
Shares Outstanding
131.79M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2021 | Dr. Steven Brooks, Chief Medical Officer | 300.0K | — | — | 16.7K | — | — | 316.7K | 5.26% | ↗ |
| 2 | 2021 | Dr. Catherine Pachuk, Chief Scientific Officer and Executive Vice President | 298.8K | — | — | — | — | — | 298.8K | 0.00% | ↗ |
| 3 | 2021 | Amy Chandler, Former Executive Vice President of Regulatory Affairs and Quality Management Systems | 201.8K | — | — | 10.8K | — | — | 212.6K | 5.09% | ↗ |
| 4 | 2021 | James Sapirstein, former Interim Chief Executive Officer | 90.0K | — | — | 113.1K | — | — | 203.1K | 55.69% | ↗ |
| 5 | 2021 | Dr. Neil J. Campbell, former Chief Executive Officer | 110.2K | — | — | 83.3K | — | — | 193.5K | 43.06% | ↗ |
| 6 | 2021 | Roger Schaller, former Executive Vice President of Commercial Operations | 165.5K | — | — | 7.4K | — | — | 173.0K | 4.30% | ↗ |
| 7 | 2021 | David Barthel, Chief Executive Officer | 58.3K | — | — | — | — | — | 58.3K | 0.00% | ↗ |
| 8 | 2021 | Dr. Vithalbhai Dhaduk, Chairman and former Interim Chief Executive Officer | — | — | — | 48.2K | — | — | 48.2K | 100.00% | ↗ |
| 9 | 2020 | Dr. Satish Chandran, CTO | 237.8K | — | — | — | — | — | 237.8K | 0.00% | ↗ |
| 10 | 2020 | Dr. Catherine Pachuk, Chief Scientific Officer and Executive Vice President | 227.9K | — | — | — | — | — | 227.9K | 0.00% | ↗ |
| 11 | 2020 | Dr. Cathy Pachuk, CSO | 227.9K | — | — | — | — | — | 227.9K | 0.00% | ↗ |
| 12 | 2020 | Dr. Neil J. Campbell, former Chief Executive Officer | 64.2K | — | — | 26.0K | — | 50.0K | 140.3K | 18.56% | ↗ |
| 13 | 2020 | Dr. Neil J. Campbell, CEO | 64.2K | — | — | — | — | 50.0K | 114.2K | 0.00% | ↗ |
| 14 | 2020 | Ralph Makar, CEO | — | — | — | — | — | 110.0K | 110.0K | 0.00% | ↗ |
| 15 | 2020 | Bruce Harmon, CFO | 21.7K | — | 12.5K | 6.3K | — | 30.0K | 70.5K | 26.60% | ↗ |
| 16 | 2020 | Nicholas DeVito, CEO, CFO | 20.0K | — | — | — | — | 20.0K | 40.0K | 0.00% | ↗ |
| 17 | 2019 | Dr. Satish Chandran, CTO | 228.7K | — | — | — | — | — | 228.7K | 0.00% | ↗ |
| 18 | 2019 | Dr. Cathy Pachuk, CSO | 194.4K | — | — | — | — | — | 194.4K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David L. Barthel | Chief Executive Officer, Secretary & Director | 350.0K | male |
| Steven Scott Brooks FACC | Chief Medical Officer | 328.9K | — |
| Catherine J. Pachuk | Executive Vice President & Chief Scientific Officer | 325.0K | — |
| George Kovalyov | Chief Financial Officer, Treasurer & Director | 168.0K | male |
| Harrison Albert Ross | Vice President of Finance | — | male |
| Kari Jacobson | Controller | — | — |
| Claudio Rigatto | Chief Medical Officer of My Health Logic | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MRZM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
